drugset
drugset / Trial / NCT04383067

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

NCT04383067 ↗

Phase 2 Unknown 20 enrolled Sheba Medical Center
NaSingle-groupOpen-labelTreatment

Summary

An autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients.

Timeline

Start
2020-05-12
Primary completion
2022-06-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic 720000 iu/kg —

Indications

urothelial carcinoma